Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Summit Therapeutics has not consistently reported at a specific time, with recent reports occurring both before market open and after market close, making Day 0 moves reflect either anticipation or initial reaction depending on the quarter.

Summit Therapeutics has exhibited extreme volatility around earnings events, with an average absolute Day 0 move of 5.41% and Day +1 move of 8.34%. The historical pattern shows significant two-day swings, with the Day 0 range averaging 9.18% and Day +1 range averaging 9.42%, indicating sustained volatility that extends well beyond the initial reaction.

The most dramatic moves occurred in early 2025 and late 2024, when the stock experienced Day 0 declines exceeding 14% (February 2025: -14.83%; October 2024: -14.57%), followed by varied Day +1 reactions. More recently, April 2026 saw a positive Day 0 move of 3.02% followed by a severe Day +1 decline of 24.91%, demonstrating how initial optimism can quickly reverse. The July 2026 earnings showed more muted volatility with a 1.63% Day 0 gain followed by an 8.81% Day +1 decline.

Investors should prepare for substantial price swings in both directions, as the stock has shown no consistent directional bias but has reliably delivered double-digit intraday ranges. The pattern suggests that even seemingly positive initial reactions can be followed by significant reversals as the market digests clinical updates and cash burn implications.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 9.70% ($1.56) for the week of November 6, 2026 expiration, which is notably higher than the average Day 0 move of 5.41% but roughly in line with the average Day +1 move of 8.34%. This suggests options traders are anticipating volatility consistent with Summit's recent earnings history, though the 94.99% implied volatility reflects elevated uncertainty around this particular release.

Part 3: What Analysts Are Saying

Analysts maintain a strongly bullish stance on Summit Therapeutics, with the stock carrying an average recommendation of 4.22 out of 5.0, firmly in buy territory. The consensus is supported by 11 Strong Buy ratings and 7 Hold ratings among the 18 analysts covering the stock, with no sell recommendations. This represents an unchanged sentiment compared to one month ago, indicating stable conviction despite recent stock volatility.

The average price target of $29.14 implies substantial upside of 81.8% from the current price of $16.03. The range of targets is wide, spanning from a low of $11.90 to a high of $43.00, reflecting divergent views on ivonescimab's commercial potential and the probability of clinical success. Goldman Sachs anchors the bullish end with its $41 target, while more conservative analysts cluster in the mid-$20s range.

The lack of any deterioration in sentiment is noteworthy given Summit's recent earnings misses and the broader biotech sector's challenges. This suggests analysts remain focused on the long-term value proposition of ivonescimab rather than near-term financial performance, viewing current losses as an acceptable cost of advancing a potentially transformative cancer therapy. The concentration of Strong Buy ratings indicates high conviction among the bull case proponents, though the presence of seven Hold ratings suggests some analysts prefer to wait for additional clinical data before recommending aggressive accumulation.

Part 4: Technical Picture

Summit Therapeutics enters earnings with a deteriorating technical picture, as the Barchart Technical Opinion has shifted from a 24% Buy signal one month ago to a 40% Sell signal currently, with the weakness accelerating over the past week (24% Sell last week). This rapid reversal in momentum suggests growing technical pressure as the stock approaches its quarterly report.

Timeframe Analysis:

• Short-term (Hold): Neutral reading indicates near-term momentum has stalled after recent volatility
• Medium-term (50% Sell): Moderate sell signal suggests the intermediate trend has turned negative
• Long-term (50% Sell): Moderate sell signal reflects sustained weakness in the longer-term trend structure

Trend Characteristics: The combination of Minimum strength and Weakest direction indicates Summit is in a fragile technical environment with limited momentum support heading into the earnings release.

The stock is currently trading at $16.03, positioned below its 20-day ($16.07), 50-day ($16.06), and 200-day ($16.18) moving averages, but above its 5-day ($15.57), 10-day ($15.63), and 100-day ($15.08) moving averages. This mixed positioning reflects recent short-term stabilization after a period of weakness, though the failure to reclaim key intermediate-term averages suggests resistance overhead.

The proximity to the 50-day moving average at $16.06 represents immediate resistance, while the 200-day average at $16.18 marks a more significant technical hurdle. Support appears clustered near the 100-day average at $15.08, which has provided a floor during recent weakness. The overall technical setup is cautionary heading into earnings, with the deteriorating Barchart Opinion signal and positioning below key moving averages suggesting limited technical cushion if the company disappoints. Given the stock's history of extreme post-earnings volatility and current weak momentum, traders should be prepared for significant downside risk if results or guidance fall short of expectations.